Ruxolitinib Treatment for Primary and Secondary Myelofibrosis Before and After Stem Cell Transplant

This clinical trial aims to explore the effectiveness of a drug called ruxolitinib for patients diagnosed with primary and secondary myelofibrosis, a condition where the bone marrow is replaced by scar tissue. The study focuses on patients who are set to undergo a hematopoietic stem cell transplantation, a procedure that can help restore the body's ability to produce healthy blood cells. The importance of this study lies in its potential to improve the transplantation process and reduce the risk of complications, ultimately enhancing the quality of care for individuals living with myelofibrosis. Participants in this study will receive ruxolitinib orally starting 8 weeks before the transplantation and continuing until approximately 14 days prior to the conditioning regimen. After the transplant, they will receive ruxolitinib again until around 7 months post-transplant, followed by a gradual reduction over 2 months. The study also involves different conditioning regimens depending on the patient's specific needs, and various tests like CT scans, blood sample collections, and bone marrow biopsies to monitor the progress. The primary outcome measured is the incidence of a complication called graft versus host disease (GVHD), which will be compared to a fixed benchmark from a previous study.